Objective: Tongue squamous cell carcinoma is one of the most common oral tumors. Human papillomavirus (HPV) infection has been proposed as a risk factor for head and neck squamous cell carcinoma, particularly oropharyngeal squamous carcinoma. Methods: In this study, we retrospectively analyzed HPV infection in 121 Chinese patients with tongue squamous cell carcinoma in Guangdong Province. Polymerase chain reaction of HPV DNA and immunohistochemistry staining of p16 protein were used to identify the presence of HPV in formalin-fixed paraffin-embedded samples. Results: HPV DNA was detected in 15.7% (n = 19) of tongue squamous cell carcinoma patients, with HPV16 being the most common type (n = 8, 42.1%). p16 staining did not correlate with detection of HPV DNA. Male sex was associated with HPV-positive tongue squamous cell carcinoma, whereas there were no significant differences in alcohol consumption, smoking, or age when tumors were stratified by HPV. Conclusion: Our study showed that HPV infection contributed to tongue squamous cell carcinoma in a small cohort of patients in Guangdong Province, China. Further investigation is needed to confirm whether HPV is a causal factor for tongue squamous cell carcinoma.
LINC01089 suppresses the malignant progression of breast, colorectal, and non-small cell lung cancers. However, the function of LINC01089 in thyroid cancer has not yet been elucidated. Here, The Cancer Genome Atlas (TCGA) database showed that LINC01089 expression is remarkably reduced in thyroid cancer tissues. Lower LINC01089 expression was correlated with higher tumor stage and regional lymph node metastasis. Furthermore, LINC01089 overexpression effectively blocked thyroid cancer cell proliferation, migration, and invasion. LINC01089 acted as a competing endogenous RNA for miR-27b-3p, thus inhibiting miR-27b-3p expression. miR-27b-3p overexpression promoted the proliferation, migration, and invasion of thyroid cancer, reversing the effect of LINC01089 overexpression on thyroid cancer. Fibulin-5 (FBLN5) was discovered as a target of miR-27b-3p in thyroid cancer. FBLN5 expression was found to be underexpressed in thyroid cancer and was enhanced and reduced by LINC00987 overexpression and miR-27b-3p overexpression, respectively. Furthermore, FBLN5 knockdown promoted the malignant progression of thyroid cancer cells by counteracting the effect of LINC00987. In conclusion, LINC01089 plays a tumor-suppressive role by binding miR-27b-3p to increase FBLN5 expression, confirming that LINC01089 has tremendous potential to become a therapeutic target for thyroid cancer treatment.